WORLD'S LARGEST MARKET RESEARCH RESOURCE — 1,519,265 REPORTS

 
 
• SEARCH FOR A REPORT

Viewing report

Search
Enter keywords, a title or a report id number below.
Advanced

• ORDER BY FAX

Order By Fax

• SELECT SITE CURRENCY

Select a currency for use throughout the site



  • Electronic (PDF) Information Icon
  • Site License Information Icon
  • Enterprisewide Information Icon
Live Chat Live Help Software for Website

ARDEA - Entering the Pivotal Phase

MP Advisors, September 2011

After a long wait, Ardea (RDEA) reached an agreement with the FDA on the proposed PhIII development plans for Lesinurad (RDEA594, Urate Transporter regulator, Gout, PhIII) and expects to initiate the trials by 4Q11. There is a major unmet medical need for a better treatment option for the majority of gout pts. How will Lesinurad target the WW gout market? Management plans on the development/partnering etc. of Lesinurad is discussed in the report released on 12th September, 2011 on RDEA titled “Entering the Pivotal Phase”

- Ardea
- Allopurinol
- BAY 86-9766
- Febuxostat
- Gout
- Hyperuricemia
- Lesinurad
- Refractory Gout
- RDEA
- Uloric

Customers who bought this item also bought